切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (01) : 21 -26. doi: 10.3877/cma.j.issn.2095-3224.2016.01.05

所属专题: 文献

青年专家论坛

中期和局部晚期老年直肠癌辅助放化疗进展
刘文扬1, 金晶1,()   
  1. 1. 100021 北京,中国医学科学院 北京协和医学院肿瘤医院放疗科
  • 收稿日期:2016-01-17 出版日期:2016-02-25
  • 通信作者: 金晶
  • 基金资助:
    国家自然科学基金资助项目(81272510)

Treatment advance of (neo) adjuvant chemoradiation for the elderly intermediate and locally advanced rectal cancer patients

Wenyang Liu1, Jing Jin1,()   

  1. 1. Department of Radiotherapy, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
  • Received:2016-01-17 Published:2016-02-25
  • Corresponding author: Jing Jin
  • About author:
    Corresponding author: Jin Jing, Email:
引用本文:

刘文扬, 金晶. 中期和局部晚期老年直肠癌辅助放化疗进展[J/OL]. 中华结直肠疾病电子杂志, 2016, 05(01): 21-26.

Wenyang Liu, Jing Jin. Treatment advance of (neo) adjuvant chemoradiation for the elderly intermediate and locally advanced rectal cancer patients[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 21-26.

直肠癌是我国及世界范围内最常见的肿瘤之一,其中的高龄患者比例逐年增加。由于缺乏针对高龄患者的前瞻性循证医学证据,目前高龄患者综合治疗的标准方案尚待明确,相当比例的高龄患者并未得到最佳的综合治疗。本文将主要从老年直肠癌的流行病学、治疗模式,尤其是(新)辅助放化疗方面,系统回顾现有资料,探讨中期及局部晚期老年直肠癌的最佳治疗模式。

Rectal cancer is one of the most commonly diagnosed cancers in China and worldwide, with an increasing trend in the proportion of elderly patients. However, as the prospective evidence designed specifically for treating this population is sparse, and the treatment algorithms for these patients become controversial, it is clear that a significant percentage of elderly rectal cancer patients has been treated less than optimally. This paper provides overviews of the recent data on epidemiology, treatment modality, especially (neo) adjuvant chemoradiation in the treatment of older rectal cancer patients, and to discuss the optimal treatment algorithm for the intermediate and locally advanced rectal cancer in the elderly.

[1]
Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. Journal of Clinical Oncology, 2015, 33(32): 3826-3833.
[2]
Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res, 2015, 27(1): 2-12.
[3]
Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol, 2009, 20(1): 5-16.
[4]
Li M, Gu J. Changing patterns of colorectal cancer in China over a period of 20 years. World J Gastroenterol, 2005, 11(30): 4685-4688.
[5]
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. Jama, 2004, 291(22): 2720-2726.
[6]
Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship Between Age at Diagnosis and Treatments. Journal of the American Geriatrics Society, 1985, 33(9): 585-589.
[7]
Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol, 2015, 26(2): 288-300.
[8]
Kunkler IH, Audisio R, Belkacemi Y, et al. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Ann Oncol, 2014, 25(11): 2134-2146.
[9]
Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol, 2015, 26(3): 463-476.
[10]
Group, C. C. C. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet, 2000, 356(9234): 968-974.
[11]
Larsen SG, Wiig JN, Tretli S, et al.Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis, 2006, 8(3): 177-185.
[12]
Rutten HJ, den Dulk M, Lemmens VE, et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol, 2008, 9(5): 494-501.
[13]
Kiran RP, Attaluri V, Hammel J, et al. A novel nomogram accurately quantifies the risk of mortality in elderly patients undergoing colorectal surgery. Ann Surg, 2013, 257(5): 905-908.
[14]
Townsley C, Pond GR, Peloza B, et al.Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol, 2005. 23(16): 3802-3810.
[15]
Townsley C, Pond GR, Peloza B, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol, 2005, 55(3): 231-240.
[16]
Fiorica F, Cartei F, Licata A, et al.Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev, 2010, 36(7): 539-549.
[17]
Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 2006, 355(11): 1114-1123.
[18]
Gérard JP, Conroy T, Bonnetain F,et al.Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 2006, 24(28): 4620-4625.
[19]
Sauer R, Becker H, Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
[20]
Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol, 2012, 23(10): 2479-2516.
[21]
Sebag-Montefiore D, Stephens RJ, Steele R, et al.Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 2009, 373(9666): 811-820.
[22]
Ngan SY, Burmeister B, Fisher RJ, et al.Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. Journal of Clinical Oncology, 2012, 30(31): 3827-3833.
[23]
Peeters KC, Marijnen CA, Nagtegaal ID,et al.The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Annals of surgery, 2007, 246(5): 693-701.
[24]
Tan E, Tilney H, Thompson M, et al.The United Kingdom National Bowel Cancer Project-epidemiology and surgical risk in the elderly. European Journal of Cancer, 2007, 43(15): 2285-2294.
[25]
Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol, 2002, 20(5): 1192-1202.
[26]
Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer, 1990, 66(1): 49-55.
[27]
Pignon T, Horiot JC, Bolla M, et al.Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol, 1997, 42(2): 107-120.
[28]
Shahir MA, Lemmens VE, van de Poll-Franse LV, et al.Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer, 2006, 42(17): 3015-3021.
[29]
Rutten H, den Dulk M, Lemmens V, et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. Eur J Cancer, 2007, 43(15): 2295-2300.
[30]
Maas HA, Lemmens VE, Nijhuis PH, et al. Benefits and drawbacks of short-course preoperative radiotherapy in rectal cancer patients aged 75 years and older. Eur J Surg Oncol, 2013, 39(10): 1087-1093.
[31]
Lorchel F, Peignaux K, Créhange G,et al.Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol, 2007, 31(4): 436-441.
[32]
Pasetto LM, Friso ML, Pucciarelli S, et al. Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res, 2006, 26(5B): 3913-3923.
[33]
Pettersson D, Holm T, Iversen H,et al.Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. British Journal of Surgery, 2012, 99(4): 577-583.
[34]
Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. British Journal of Surgery, 2010, 97(4): 580-587.
[35]
Pettersson D, Lörinc E, Holm T, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. British Journal of Surgery, 2015, 102(8): 972-978.
[36]
Ceelen W, Fierens K, Van Nieuwenhove Y, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer, 2009, 124(12): 2966-2972.
[37]
Neugut AI, Fleischauer AT, Sundararajan V, et al.Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol, 2002, 20(11): 2643-2650.
[38]
Martijn H, Vulto JC.Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer, 2007, 43(15): 2301-2306.
[39]
Dobie SA, Warren JL, Matthews B, et al. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer, 200, 112(4): 789-799.
[40]
Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol, 2010, 28(10): 1638-1644.
[41]
François E, Azria D, Gourgou-Bourgade S, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol, 2014, 110(1): 144-149.
[42]
Jiang DM, Raissouni S, Mercer J, et al. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. Annals of Oncology, 2015, 6(10): 2102-2106.
[1] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[2] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[3] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[4] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[7] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[8] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[9] 郑民华, 蒋天宇, 赵轩, 马君俊. 中国腹腔镜直肠癌根治术30年发展历程与未来[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 591-595.
[10] 池畔, 黄胜辉. 中国腹腔镜直肠癌根治术30年来的巨大进步[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 596-600.
[11] 李明, 屠松, 闫鹏, 钱军, 高鹏程, 许文山, 杨发英, 胡振涛, 单永玮. 应用前列腺电切镜引导置管治疗直肠低位吻合口漏研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 603-606.
[12] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[13] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?